Eisai Global Executive and Leadership Team

Haruo Naito, the Director, Representative Corporate Officer and Chief Executive Officer at Eisai Global, directs the overarching human health care philosophy that defines the pharmaceutical manufacturing operations. Naito architects long-term strategic goals, ensuring the company maintains a competitive edge in global drug development. By overseeing the integration of research and development with patient-centered healthcare delivery, the Chief Executive Officer aligns internal resources with evolving medical needs across North America, Europe, and Asia Pacific. This leadership role involves constant collaboration with the Board to refine corporate governance and market expansion strategies. Haruo Naito drives the organizational culture, fostering innovation in medicine production while maintaining high standards of corporate responsibility. Through consistent focus on therapeutic breakthroughs, the Director secures the company's position as a leader in the pharmaceutical sector, ultimately delivering value to patients and stakeholders worldwide.

Tatsuyuki Yasuno, the Chairman & Chief Executive Officer & Eisai Inc Region President (Americas) at Eisai Global, manages the strategic direction and operational execution within the North American market. Yasuno oversees the expansion of pharmaceutical manufacturing capabilities, ensuring that regional initiatives align with the broader human health care mission. By coordinating with cross-functional teams, the Region President drives the commercialization of new medicines and optimizes supply chain efficiency across the United States. This leadership role requires balancing complex regulatory requirements with the need for rapid innovation in patient-centered healthcare solutions. Tatsuyuki Yasuno monitors market trends to adjust business models, ensuring sustained growth and operational excellence. Through active engagement with regional stakeholders, the Chairman secures the company's market presence, effectively translating global research objectives into tangible health outcomes for patients throughout the Americas.

Brian Harraka, the Vice President & Chief Financial Officer at Eisai Global, manages the financial health and fiscal strategy of the pharmaceutical manufacturing enterprise. Harraka oversees capital allocation, budgeting, and financial reporting, ensuring that resources support the company's extensive research and development pipeline. By analyzing market data and operational costs, the Chief Financial Officer provides the insights necessary for the Board to make informed investment decisions regarding new drug production. This leadership role involves maintaining rigorous financial controls while supporting the expansion of business-to-business and business-to-consumer operations across global regions. Brian Harraka drives financial efficiency, optimizing the balance sheet to facilitate long-term sustainability and innovation. Through disciplined fiscal management, the Vice President ensures that the company remains well-positioned to fund critical healthcare initiatives, ultimately supporting the delivery of advanced medical solutions to patients worldwide.

Hiroyuki Murayama, the President (Japan) & Promotion Department Manager, Product Strategy at Eisai Global, manages the commercial strategy and product positioning within the Japanese market. Murayama oversees the promotion of pharmaceutical products, ensuring that marketing efforts align with the company's human health care approach. By analyzing local market dynamics and patient needs, the President (Japan) architects product strategies that maximize the impact of new therapeutic offerings. This leadership role involves coordinating with research teams to translate scientific breakthroughs into effective market messaging. Hiroyuki Murayama drives the execution of promotional campaigns, ensuring that healthcare providers and patients receive accurate information regarding medicine benefits. Through strategic oversight of product lifecycles, the Promotion Department Manager supports the company's growth objectives in Japan, effectively strengthening the brand's reputation for excellence in pharmaceutical manufacturing and patient-centered healthcare delivery.

Yanhui Feng, the President & General Manager (Eci) at Eisai Global, directs the operational activities and strategic growth within the China market. Feng oversees the manufacturing and distribution of pharmaceutical products, ensuring that regional operations adhere to the company's global standards for quality and patient care. By managing local partnerships and navigating complex regulatory environments, the General Manager (Eci) drives the expansion of the company's footprint in the Asia Pacific region. This leadership role involves aligning regional business models with the overarching human health care mission, ensuring that local patients gain access to innovative medicines. Yanhui Feng monitors market performance and operational efficiency, implementing strategies that enhance the company's competitive position. Through dedicated leadership, the President secures the company's influence in the pharmaceutical sector, effectively delivering high-quality healthcare solutions to a diverse and growing patient population.

Kenichi Nomoto, the President, Oncology Product Creation Unit at Eisai Global, manages the research and development pipeline specifically focused on cancer therapeutics. Nomoto oversees the scientific teams responsible for discovering and refining new oncology medicines, ensuring that every project aligns with the company's human health care philosophy. By directing clinical trials and laboratory research, the President, Oncology Product Creation Unit drives the development of innovative treatments that address unmet medical needs. This leadership role involves collaborating with global research centers to accelerate the transition from discovery to production. Kenichi Nomoto monitors the progress of the oncology portfolio, ensuring that resources are allocated to the most promising therapeutic candidates. Through rigorous scientific oversight, the President supports the company's mission to improve patient outcomes, effectively advancing the state of cancer care through dedicated pharmaceutical innovation.

Michael Montaigne, the President, Eisai Machinery (USA) at Eisai Global, directs the manufacturing technology and machinery operations within the United States. Montaigne oversees the development and maintenance of specialized equipment used in the production of pharmaceutical products, ensuring that all machinery meets the highest standards of precision and safety. By managing the technical teams responsible for equipment innovation, the President, Eisai Machinery (USA) drives the efficiency of the manufacturing process, enabling the company to produce high-quality medicines at scale. This leadership role involves integrating advanced engineering solutions into the pharmaceutical production line to support the company's human health care mission. Michael Montaigne monitors operational performance, implementing improvements that reduce downtime and enhance output. Through technical expertise and strategic management, the President ensures that the company's manufacturing capabilities remain robust, supporting the reliable delivery of essential healthcare products to patients.

Shawn Gallagher, the President, Partnership Management Core Functional Unit at Eisai Global, manages the strategic alliances and collaborative relationships that fuel the company's pharmaceutical development. Gallagher oversees the identification and cultivation of partnerships with research institutions, biotech firms, and healthcare providers, ensuring that these collaborations align with the company's human health care approach. By negotiating agreements and managing ongoing relationships, the President, Partnership Management Core Functional Unit drives the integration of external expertise into the company's internal research and development pipeline. This leadership role involves coordinating across departments to ensure that partnerships deliver tangible value and support the company's long-term growth objectives. Shawn Gallagher monitors the performance of these alliances, adjusting strategies to maximize the impact of collaborative efforts. Through effective partnership management, the President secures the company's access to cutting-edge innovation, ultimately enhancing the delivery of patient-centered healthcare solutions.

Toshimitsu Uenaka, the President, Epochal Precision Anti-Cancer Therapeutics at Eisai Global, directs the development of highly targeted cancer treatments. Uenaka oversees the specialized research teams focused on precision medicine, ensuring that therapeutic candidates are designed to address specific genetic and molecular markers in cancer patients. By managing the transition of these precision therapies through clinical development, the President, Epochal Precision Anti-Cancer Therapeutics drives the company's efforts to provide personalized healthcare solutions. This leadership role involves collaborating with global oncology experts to refine treatment protocols and improve patient outcomes. Toshimitsu Uenaka monitors the progress of the precision medicine portfolio, ensuring that research efforts remain focused on high-impact therapeutic areas. Through dedicated leadership in the field of anti-cancer therapeutics, the President supports the company's mission to advance human health care, effectively delivering innovative and targeted medical solutions to patients facing complex cancer diagnoses.

Makoto Hoketsu, the Vice President & Chief Information Officer at Eisai Global, directs the digital transformation and information technology infrastructure supporting pharmaceutical manufacturing. Hoketsu oversees the implementation of advanced data analytics and secure systems that facilitate research and development across global operations. By architecting scalable cloud solutions and cybersecurity frameworks, the Chief Information Officer ensures that sensitive patient and clinical data remains protected while enabling seamless collaboration between international teams. This leadership role involves integrating digital tools into the human health care model to improve operational efficiency and speed to market for new medicines. Makoto Hoketsu drives the adoption of emerging technologies, ensuring the company stays at the forefront of digital health innovation. Through strategic oversight of the IT landscape, the Vice President supports the company's mission to provide comprehensive healthcare solutions, effectively bridging the gap between complex data and patient-centered care.